Jazz Pharmaceuticals Archives -

Jazz Pharma has bolstered its pipeline of cancer drugs through a $1.3 billion licensing agreement with Werewolf Therapeutics

Jazz adds first immuno-oncology drug via $1.3bn Werewolf deal

https://pharmaphorum.com/news/jazz-adds-first-immuno-oncology-drug-via-1-3bn-werewolf-deal/

News/ News/ Sales and Marketing

Jazz breaks ground on $100m UK plant for cannabinoid drugs

Phil Taylor cannabinoid, GW Pharmaceuticals, investment, Jazz Pharmaceuticals, manufacturing 0 Comment

Jazz Pharma has started construction of a manufacturing facility in the UK that will be used to manufacture

Jazz breaks ground on $100m UK plant for cannabinoid drugs

https://pharmaphorum.com/news/jazz-breaks-ground-on-100m-uk-plant-for-cannabinoid-drugs/

Market Access/ News/ News

Wales is first UK country to fund GW’s Epidyolex for tuberous sclerosis

Phil Taylor Epidyolex, epilepsy, GW Pharma, HEOR, Jazz Pharmaceuticals, Tuberous Sclerosis Complex, Wales 0 Comment

Patients in Wales with a rare disease that causes epilepsy will be the first in the UK to

Wales is first UK country to fund GW’s Epidyolex for tuberous sclerosis

https://pharmaphorum.com/news/wales-is-first-uk-country-to-fund-gws-epidyolex-for-tuberous-sclerosis/

News/ News/ Oncology

Trial of Jazz’ cannabis drug in glioblastoma will start next year

Phil Taylor cannabinoid, glioblastoma, GW Pharma, Jazz Pharmaceuticals, Oncology, Sativex 0 Comment

An investigator-led trial of Jazz Pharma’s cannabis extract-based drug Sativex in glioblastoma – an aggressive form of brain

Trial of Jazz’ cannabis drug in glioblastoma will start next year

https://pharmaphorum.com/news/trial-of-jazz-cannabis-drug-in-hard-to-treat-glioblastoma-will-start-next-year/

Market Access/ News

Jazz lifted by third EU approval for GW Pharma’s Epidyolex

Phil Taylor cannabis, Epidyolex, epilepsy, EU, GW Pharma, Jazz Pharmaceuticals, rare disease 0 Comment

GW Pharmaceuticals’ Epidyolex has been approved in the EU for a third epilepsy indication, giving a boost for

Jazz lifted by third EU approval for GW Pharma’s Epidyolex

https://pharmaphorum.com/news/jazz-lifted-by-third-eu-approval-for-gw-pharmas-epidyolex/

News/ News/ Sales and Marketing

Jazz agrees $7.2bn deal to buy cannabis meds pathfinder GW Pharma

Phil Taylor cannabis, Epidiolex, GW Pharma, Jazz Pharmaceuticals, M&A 0 Comment

Jazz Pharma has agreed a $7.2 billion deal to by GW Pharmaceuticals and its pioneering cannabis-derived medicines, headed

Jazz agrees $7.2bn deal to buy cannabis meds pathfinder GW Pharma

https://pharmaphorum.com/news/jazz-agrees-7-2bn-deal-to-buy-cannabis-meds-pathfinder-gw-pharma/

News/ News/ Sales and Marketing

Harmony’s sleep disorder drug Wakix gets US label extension

Richard Staines catalepsy, fda, Harmony Biosciences, Jazz Pharmaceuticals, narcolepsy 0 Comment

Harmony Biosciences has scored an expanded use for its Wakix narcolepsy drug to include cataplexy – a symptom

Harmony’s sleep disorder drug Wakix gets US label extension

https://pharmaphorum.com/news/harmonys-narcolepsy-drug-gets-extended-cataplexy/

News/ News/ Sales and Marketing

FDA approves Jazz Pharmaceuticals’ narcolepsy therapy

Richard Staines Jazz Pharmaceuticals, narcolepsy, neurology 0 Comment

The FDA has approved Jazz Pharmaceuticals’ sleep disorder drug Xywav, to treat daytime sleepiness in patients with narcolepsy,

FDA approves Jazz Pharmaceuticals’ narcolepsy therapy

https://pharmaphorum.com/news/fda-approves-jazz-pharmaceuticals-narcolepsy-therapy/

News/ News/ Oncology

Jazz targets US launch of SCLC drug after FDA grants fast review

Richard Staines cancer, fda, Jazz Pharmaceuticals, lung cancer, PharmaMar 0 Comment

PharmaMar and Jazz Pharmaceuticals have announced the FDA has granted a six-month Priority Review for their lurbinectedin for

Jazz targets US launch of SCLC drug after FDA grants fast review

https://pharmaphorum.com/news/jazz-targets-us-launch-of-sclc-drug-after-fda-grants-fast-review/

Trending

Jazz Pharmaceuticals

Login